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Hepatocellular carcinoma (HCC) is one of the most common
cancers in Asia and Africa (Okuda et al, 1987; Di Bisceglie et al,
1988). However, the molecular mechanism of hepatocarcino-
genesis is still unclear. It is generally assumed that the non-random
loss of heterozygosity (LOH) detected by restriction fragment
length polymorphism (RFLP) markers or allelic imbalance (AI) by
using microsatellite markers in a specific region may indicate the
existence of a tumour suppressor gene at or near the tested region
which is involved in the development or progression of HCC
(Fujimori et al, 1991; Weinberg, 1991). AI encompasses LOH and
allelic gain; however, cases with marked reduction of intensity of
one allele represent LOH rather than allelic gain (Elder et al,
1994). Thus, many chromosomal arms have been reported in HCC
as candidate sites for putative tumour suppressor genes, including
1p, 4q, 8p, 13q, 16q and 17p (Tsuda et al, 1990; Fujimori et al,
1991). Among these alterations, LOH on chromosome 16q has
been reported to occur more frequently in HCCs of poor differen-
tiation or large size, and with metastasis (Tsuda et al, 1990;
Nishida et al, 1992). Recently, in an allelotype study on HCC, we
also identified frequent LOH (LOH > 50%) on chromosome 16q,
confirming that candidate tumour suppressor genes may be located
on this chromosome (Piao et al, 1998).
Deletion and rearrangement of chromosome 16q are also
frequently seen in other cancers, including breast cancer, prostate
carcinoma and Wilms’ tumour (Carter et al, 1990; Maw et al,
1992; Lindblom et al, 1993; Cleton-Jansen et al, 1994; Dorion-
Bonnet et al, 1995; Suzuki et al, 1996; Latil et al, 1997). The
common deleted regions in these tumours have been identified at
16q22.1 and 16q24-qter (Maw et al, 1992; Dorion-Bonnet et al,
1995; Suzuki et al, 1996). However, it is difficult to ascertain
whether LOH reported in different types of cancers is due to the
loss of the same tumour suppressor genes in different cancers, or
to the loss of distinct genes specific for each tumour type, because
different microsatellite or RFLP markers had been used in these
studies.
In an effort to define the commonly affected region on chromo-
some 16q for further positional cloning of the putative tumour
suppressor gene in HCC, we performed detailed deletion mapping
studies of chromosome 16q in 41 HCCs with 37 microsatellite
markers.
MATERIALS AND METHODS
Tissue selection and DNA extraction
HCCs and adjacent non-tumourous tissues were obtained from 41
patients with HCC. Of these, 39 were obtained from surgical
resections performed at Yonsei University College of Medicine,
Seoul, Korea, from January 1995 to September 1996. Two HCC
tissues were gifts from Dr Uchida, Nihon University School of
Medicine, Tokyo, Japan. There were 28 (68.3%) cases positive for
HBsAg, two (4.9%) were positive for anti-hepatitis C virus anti-
body, and the remaining 11 (26.8%) were unrelated to the viral
markers. Twenty-four (58.5%) HCCs were detected in cirrhotic
livers. Nine cases (22%) were small (≤ 3 cm) and 32 (78%) were
advanced (> 3 cm) HCCs (Yumoto et al, 1995). Tumour differenti-
ation was graded according to the criteria of Kanai et al (1987):
seven (17%) HCCs were well-differentiated, 23 (56%) were
moderately differentiated and 11 (27%) were poorly differentiated
according to this grading system. The samples were freshly
obtained, immediately frozen in liquid nitrogen and stored at
–70°C until analysis. A microdissection technique using a cryostat
was used to separate the tumour cells from adjacent normal
tissues. Genomic DNA was prepared by the sodium dodecyl
sulphate (SDS)–proteinase K and phenol–chloroform extraction
method (Gruis et al, 1993).
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Summary Hepatocellular carcinoma (HCC) frequently shows an allelic imbalance (AI) on chromosome 16q. In order to define the commonly
affected regions on chromosome 16q, we assessed AI studies in 41 HCCs using a panel of 37 microsatellite markers. Thirty-five cases (85%)
showed AI at one or more loci. Among the 35 cases with AI, 21 cases showed multiple AI, suggesting the wide scope of deletion on the long
arm of chromosome 16, and the remaining 14 cases showed partial AI. Detailed deletion mapping identified two independent commonly
deleted regions on this chromosome arm. These included the D16S3106 locus and D16S498 locus. In conclusion, we have demonstrated
frequent AI on 16q in HCCs and identified two loci with frequent AI, which may harbour new tumour suppressor genes.
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Analysis of AI using microsatellite markers
A total of 37 microsatellite markers were used, which were
obtained from Research Genetics (Huntsville, AL, USA). These
are shown in Table 1. Hot-start polymerase chain reactions (PCRs)
were performed in a Perkin-Elmer 480 thermal cycler with 20 ml
volume containing 1.5 mM magnesium chloride, 20 pmol primer,
0.2 mM each dATP, dGTP, dTTP, 5 mM dCTP, 1 mCi [a32P]-dCTP
(3000 Ci mmol–1; NEN DuPont, Boston, MA, USA), 50 ng sample
DNA, 1 ´ PCR buffer (containing 20 mM Tris–HCl, pH 8.4,
50 mM potassium chloride) and 1.25 U Taq polymerase (GIBCO-
BRL, Grand Island, NY, USA). DNA amplification was performed
with 25 cycles consisting of denaturation at 95°C for 30 s, primer
annealing at 55°C for 30 s, and elongation at 72°C for 15 s.
PCR products were diluted twofold with stop solution (95%
formamide, 20 mM EDTA, 0.05% xylene cyanol and 0.05%
bromophenol blue). Three microlitres of mixture were loaded onto
6% denaturing polyacrylamide gel containing 5.6 M urea. The gel
was dried and exposed to Kodak XAR-5 film (Kodak, Rochester,
NY, USA). AI was scored when band intensity of one allelic
marker was significantly decreased (more than 70% reduction) in
tumour DNA compared with that in normal DNA (Elder et al,
1994).
RESULTS
Defining a minimal region of AI on chromosome 16q
Forty-one HCCs were screened for AI with a panel of 37
microsatellite markers specific for chromosome 16q loci. This
made it possible to find the regions showing frequent (> 60%) AI
and mapping of the deletion regions on chromosome 16q. The
representative autoradiographs of the several markers are shown in
Figure 1. All 41 cases were informative at several loci on 16q and
35 cases (85%) showed AI at one or more loci. The overall
frequency of deletion at each locus and its linkage ordering based
on the Genethon Linkage Map is shown in Table 1 (Dib et al,
1996). Markers D16S498 (64%) showed the highest AI of the
markers tested (Table 1). The patterns of AI at several specific loci
are shown in Figure 2. Two independent regions of frequent AI
were defined: the first region was between D16S3059 and
D16S3033, encompassed by approximately a 2 cM region, and
defined by the D16S3106 locus; the second region was defined by
the D16S498 locus between the D16S520 and D16S3074 loci, and
encompassed approximately by a 2 cM region (Figure 2). Several
independent regions of relatively frequent (> 40%) AI were also
Table 1 Allelic imbalance (AI) on 16q in 41 hepatocellular carcinomas
Locus Chromosome site AI/Informative Percentage
D16S3071 11/26 42.3
D16S494 16q21 12/26 46.2
D16S3132 17/33 51.5
D16S3143 10/20 50.0
D16S514 16q21 14/26 53.9
D16S3129 7/17 41.2
D16S503 16q21 6/20 30.0
D16S400 16q21 7/13 53.8
D16S3050 14/31 45.2
D16S3067 10/27 37.0
D16S3095 9/32 28.1
D16S3059 9/26 39.1
D16S3106 14/22 63.6
D16S3033 11/27 40.7
D16S512 16q22.1 12/35 34.3
D16S515 10/34 29.4
D16S3097 12/33 36.4
D16S3101 9/24 37.5
D16S3125 8/19 42.1
D16S518 13/29 44.8
D16S3029 11/24 45.8
D16S3049 9/25 36.0
D16S3096 10/24 41.7
D16S516 16q24.1 15/29 51.7
D16S3144 5/12 41.7
D16S504 10/25 40.0
D16S3040 7/19 36.8
D16S507 10/20 50.0
D16S505 18/36 50.0
D16S402 16q24.2 16/33 48.5
D16S3037 14/29 48.5
D16S520 12/28 42.1
D16S498 22/34 64.7
D16S3074 11/29 37.9
D16S3048 8/21 38.1
D16S3063 5/25 20.0
D16S413 16q24.3 10/26 38.5
Figure 1 Representative autoradiographs of allelic imbalance (AI). The
carcinoma (C) and corresponding non-tumourous tissue (N) are shown with
microsatellite markers indicated at the left. AI is seen in cases 9, 10, 11, 12,
15 and 21due to loss of the lower allele in cases 9, 11 and 12, and oss of the
upper allele in cases 10, 15 and 21 with marker D16S3106. AI is seen in
casse 9, 11 and 12 with markers of D16S516 and D16S498
NC NC NC NC NC NC
91 01 11 2 1 52 1
D16S3106
D16S516
D16S498
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Figure 2 Schematic representation of allelic imbalance in hepatocellular carcinoma of 37 microsatellite markers mapping from D16S3071 to D16S413. The
markers are listed in relative positions from centromeric to the most telomeric. Thirty-five cases show AI at one or more loci according to their linkage order
n : allelic imbalance; n n: retention of heterozygosity; • : not informativeDeletion mapping of 16q in HCC 853
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defined: the first region was between D16S494 and D16S503,
encompassed by a 6 cM region, and defined by the D16S3132 and
D16S514 loci (Figure 2); the second region was between the
D16S503 and D16S3067 loci, encompassed by a 4 cM region, and
defined by the D16S400 and D16S3050 loci (Figure 2); the third
region was between the D16S3096 and D16S504 loci, encom-
passed by a 2 cM region and defined by the D16S516 locus
(Figure 2); the fourth AI region was defined by the D16S507 and
D16S505 loci. Among the 35 HCCs with AI on chromosome 16q,
21 HCCs (cases 2, 4–9, 11, 12, 16, 17, 23, 27, 30, 31, 33, 35–38,
40) showed AI at multiple informative loci, indicating a wide
scope or entire deletion on the long arm of chromosome 16
(Figure 2). The remaining 14 HCCs showed deletions involving
restricted regions of 16q.
Association of AI with clinicopathological parameters
In order to examine the relationship between AI on 16q and the
clinicopathological findings, we compared the AI of six regions
with various clinicopathological data, including HBV infection,
cirrhosis, tumour size and tumour differentiation. Most of the
HCCs having wide-scope deletion on the 16q had a trend toward
large-size tumour formation (18/21, 86%) and less (moderate and
poor) differentiation (20/21, 95%); however, there was no signifi-
cant association between the AI of 16q and clinicopathological
parameters (Table 2). HCCs with AI in D16S3106 had a trend
toward large-size tumour formation (12/14, 86% vs 4/8, 50%,
P = 0.07) and HCCs with AI in D16S498 had a tendency of less
(moderate and poor) differentiation (21/22, 95% vs 9/13, 69%,
P = 0.073). However, there was no significant association between
the two commonly deleted regions and clinicopathological
parameters (Table 2).
DISCUSSION
Non-random deletion or allelic imbalance (AI) in HCC has been
reported on chromosomes 1p, 4q, 8p, 13q, 16q and 17p (Tsuda
et al, 1990; Fujimori et al, 1991), indicating the existence of puta-
tive tumour suppressor genes on these chromosomes (Weinberg,
1991). Previously, we found that D16S752 was the most
commonly affected locus on the long arm of chromosome 16 (Piao
et al, 1998). However, this locus can not be places at specific
regions on the published linkage map (Dib et al, 1996). Therefore,
we screened an area of approximately 55 cM of 16q in 41 HCCs
to further narrow down the regions of the markers. The results
indicated that there were two independent most frequent AI on the
long arm of chromosome 16 with a panel of 37 microsatellite
common AI regions on chromosome 16q which both gave a very
comprehensive evidence of the presence of several tumour
suppressor genes involved in hepatocarcinogenesis on this
chromosomal arm.
AI on chromosome 16q has been observed at a high frequency
in HCC (Tsuda et al, 1990; Fujimori et al, 1991). Tsuda et al
(1990) detected that the common region of allelic loss on chromo-
some 16 was between the HP locus (16q22.1) and the CTRB locus
(16q22.3–q23.2) with RFLP markers. Yeh et al (1996) also
reported that the common deleted region was mapped to 16q22–23
in HCC. Frequent AI on chromosome 16q has also been reported
in other tumour types including breast cancer (Lindblom et al
,1993; Cleton-Jansen et al, 1994; Dorion-Bonnet et al, 1995),
prostate carcinoma (Carter et al, 1990; Latil et al, 1997) and
Wilms’ tumour (Maw et al, 1992). Two regions on chromosome
16q have been shown to have a very high frequency of AI in breast
cancer; one maps to region 16q22.1 and the other to 16q24.2-qter
(Cleton-Jansen et al, 1994). Similarly, Suzuki et al (1996) identi-
fied three distinct commonly deleted regions which were located
at 16q22.1–q22.3, 16q23.2–q24.1 and 16q24.3-qter in prostate
cancers. Latil et al (1997) also identified three distinct commonly
deleted regions in prostate cancers; at 16q24.3 between markers
D16S520 and D16S413, at 16q22.1 defined by markers D16S347
and D16S318, at 16q23.2 between markers D16S518 and
D16S507. Recently, Chen et al (1996) defined the minimal deleted
region in breast cancer that is most commonly affected as
16q23.3–q24.1, locus D16S518 between markers D16S515 and
D16S504, which the other two regions of interest for LOH are
located at 16q24.2, locus D16S402 and 16q21, locus D16S400.
Specific chromosomal regions showing AI in this study were
similar to those reported previously for 16q21–q24, but there were
some differences. Our study showed that two independent AI
regions (loci) were defined on chromosome 16q in HCC. Among
these two regions, the D16S498 region was in agreement with
previously described areas in prostate carcinoma; 16q24.3 at loci
between D16S520 and D16S413 (Latil et al, 1997). However, we
demonstrated that the D16S498 locus shows most frequent AI at
Table 2 Comparison of clinicopathologic features of hepatocellular carcinoma according to the alletic imbalance (AI) status of 16q
16q AI status AI of D16S3106 AI of D16S498
Variable Category Wide-scope Restricted Absent Present Absent Present Absent
Tumour size
< 3 cm 3 3 3 2 4 4 3
> 3 cm 18 11 3 12 4 18 10
Tumour differentiation
Well 1 4 2 3 3 1 4
Moderate 14 7 2 6 2 15 5
Poor 6 3 2 5 3 6 4
Cirrhosis in adjacent liver
Present 11 10 3 7 6 12 8
Absent 10 4 3 7 2 10 5
Serum HBsAg
Present 13 11 4 11 5 15 7
Absent 8 3 2 3 3 7 6854 Z Piao et al
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this region by detailed deletion mapping analysis. The D16S3106
locus, to our knowledge, had not been reported previously. We also
demonstrated four independent relatively frequent AI regions: the
first region, the D16S3132 and D16S514 loci; the second region,
the D16S400 and D16S3050 loci; the third region, the D16S516
locus; the fourth region, the D16S507 and D16S505 loci. Among
these regions, the second region was in agreement with previously
described areas in breast cancer: 16q21 at locus D16S400 (Chen
et al, 1996). However, we found that the D16S3050 locus distal to
the D16S400 locus also showed a high frequency of AI (45.2%).
Therefore, the frequently deleted region was defined by the
D16S400 and D16S3050 loci between D16S503 and D16S3067,
encompassed by a 4 cM region. The third region was in agreement
with previously described areas in prostate carcinomas; 16q24.3 at
loci between D16S518 and D16S507. We defined D16S516 as the
most commonly deleted locus in these regions using seven
microsatellite markers between D16S518 and D16S507. Although
D16S518 was reported as the most frequently affected locus
between markers D16S515 and D16S504 in breast cancer (Chen
et al, 1996), this locus did not show a high frequency of AI in
HCC. Instead, with detailed mapping we defined one independent
region of AI between markers D16S515 and D16S504, as
D16S516 (51.7%).
The association between allelic loss on chromosome 16q and
the progression of human HCC has been proposed by several
groups (Tsuda et al, 1990; Nishida et al, 1992; Yumoto et al, 1995).
Tsuda et al (1990) reported that allelic loss between HP and CTRB
loci occurred more frequently in HCCs of poor differentiation and
large size, and with metastasis. Similar results were reported in
cancer (Lindblom et al, 1993) and prostate cancer (Suzuki et al,
1996). On the other hand, Chen et al (1996) reported that frequent
LOH at a preinvasive stage of breast cancer suggests that a candi-
date tumour suppressor gene on 16q may play an important role in
breast carcinogenesis. Our results showed that AI of 16q in HCC
was very frequent and many of them showed wide-scope deletion
of the one chromosomal arm. Although we could not find any
statistically significant relationship between AI of 16q and clinico-
pathological parameters, HCCs with AI of 16q had a trend toward
large mass formation and poor differentiation. These findings
suggest that AI of 16q in HCCs might be related to the HCC
progression.
In conclusion, this study demonstrated that chromosome 16q is
highly affected by AI in HCC. We narrowed down the location of
the minimal deletion regions which are involved in two indepen-
dent regions (loci) on chromosome 16q.
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